<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39438626</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Improved efficacy of SARS-CoV-2 isolation from COVID-19 clinical specimens using VeroE6 cells overexpressing TMPRSS2 and human ACE2.</ArticleTitle><Pagination><StartPage>24858</StartPage><MedlinePgn>24858</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">24858</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-75038-4</ELocationID><Abstract><AbstractText>The cell culture-based isolation of novel coronavirus SARS-CoV-2 from clinical specimens obtained from patients with suspected COVID-19 is important not only for laboratory diagnosis but also for obtaining live virus to characterize emerging variants. Previous studies report that monkey kidney-derived VeroE6/TMPRSS2 cells allow efficient isolation of SARS-CoV-2 from clinical specimens because these cells show stable expression of the receptor molecule monkey ACE2 and the serine-protease TMPRSS2. Here, we demonstrated that VeroE6 cells overexpressing human ACE2 and TMPRSS2 (Vero E6-TMPRSS2-T2A-ACE2 cells) are superior to VeroE6/TMPRSS2 for isolating SARS-CoV-2 from clinical specimens. These cells showed a 1.6-fold increase in efficiency in SARS-CoV-2 isolation, and were particularly effective for clinical specimens with a relatively low viral load (&lt; 10<sup>6</sup> copies/mL). When using vesicular stomatitis virus (VSV) pseudoviruses (VSV/SARS-2pv) bearing the spike proteins of all of the tested SARS-CoV-2 strains, Vero E6-TMPRSS2-T2A-ACE2 cells showed a 2- to fourfold increase in infectivity. Furthermore, the results of virus titration and neutralization antibody assays using Vero E6-TMPRSS2-T2A-ACE2 cells were different from those using VeroE6/TMPRSS2, highlighting the importance of selecting appropriate cell culture systems to determine SARS-CoV-2 infectivity.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Kinoshita</LastName><ForeName>Hitomi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yamamoto</LastName><ForeName>Tsukasa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kuroda</LastName><ForeName>Yudai</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inoue</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miyazaki</LastName><ForeName>Kaya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ohmagari</LastName><ForeName>Norio</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tokita</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Phu Hoang Anh</ForeName><Initials>PHA</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamada</LastName><ForeName>Souichi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harada</LastName><ForeName>Shizuko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanno</LastName><ForeName>Takayuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Kenichiro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Masumichi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shirato</LastName><ForeName>Kazuya</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Virology III, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takayama</LastName><ForeName>Ikuyo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Shinji</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Center for Influenza and Respiratory Viruses, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saito</LastName><ForeName>Tomoya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Emergency Preparedness and Response, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ebihara</LastName><ForeName>Hideki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suzuki</LastName><ForeName>Tadaki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maeda</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Veterinary Science, National Institute of Infectious Diseases, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fukushi</LastName><ForeName>Shuetsu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. fukushi@niid.go.jp.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>JP21fk0108615</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant><Grant><GrantID>JP22fk0108509</GrantID><Agency>Japan Agency for Medical Research and Development</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="D012697">Serine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.-</RegistryNumber><NameOfSubstance UI="C421305">TMPRSS2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="C000705307">ACE2 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="Y">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012697" MajorTopicYN="Y">Serine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ACE2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">TMPRSS2</Keyword><Keyword MajorTopicYN="N">Virus isolation</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>22</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39438626</ArticleId><ArticleId IdType="pmc">PMC11496680</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-75038-4</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-75038-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature579, 270–273. 10.1038/s41586-020-2012-7 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol5, 536–544. 10.1038/s41564-020-0695-z (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095448</ArticleId><ArticleId IdType="pubmed">32123347</ArticleId></ArticleIdList></Reference><Reference><Citation>Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature603, 679–686. 10.1038/s41586-022-04411-y (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942855</ArticleId><ArticleId IdType="pubmed">35042229</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachmann, N. P. et al. Neutralization escape by SARS-CoV-2 omicron subvariants BA.2.12.1, BA.4, and BA.5. N. Engl. J. Med.387, 86–88. 10.1056/NEJMc2206576 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258748</ArticleId><ArticleId IdType="pubmed">35731894</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N. &amp; Bull, R. A. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol.32, e2381. 10.1002/rmv.2381 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9349777</ArticleId><ArticleId IdType="pubmed">35856385</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Statement on the fifteenth meeting of the International Health Regulations (2005) emergency committee regarding the coronavirus disease (COVID-19) pandemic (2023) World Health Organization. https://www.who.int/news/item/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic?adgroupsurvey=%7Badgroupsurvey%7D&amp;gclid=EAIaIQobChMI4Ojtsdbe_gIVjQRyCh07igt4EAAYASACEgJ9pfD_BwE&amp;fbclid=IwAR2M8EAyiSrAodhK9p-X582nHkP2AigpSX8pYIsLsPwqYh4SG26RGokGe7E (2023).</Citation></Reference><Reference><Citation>Cheng, K. et al. WHO declares the end of the COVID-19 global health emergency: lessons and recommendations from the perspective of ChatGPT/GPT-4. Int. J. Surg.109, 2859–2862. 10.1097/JS9.0000000000000521 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10498859</ArticleId><ArticleId IdType="pubmed">37246993</ArticleId></ArticleIdList></Reference><Reference><Citation>Wannigama, D. L. et al. Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1. Lancet Infect. Dis.10.1016/S1473-3099(24)00155-5 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38522445</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO. Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases. Available: https://www.who.int/publications/i/item/10665-331501 (2020).</Citation></Reference><Reference><Citation>Shirato, K. et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn. J. Infect. Dis.73, 304–307. 10.7883/yoken.JJID.2020.061 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32074516</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren, X. et al. Analysis of ACE2 in polarized epithelial cells: surface expression and function as receptor for severe acute respiratory syndrome-associated coronavirus. J. Gen. Virol.87, 1691–1695. 10.1099/vir.0.81749-0 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16690935</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuyama, S. et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. USA117, 7001–7003. 10.1073/pnas.2002589117 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7132130</ArticleId><ArticleId IdType="pubmed">32165541</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada, S. et al. Assessment of SARS-CoV-2 infectivity of upper respiratory specimens from COVID-19 patients by virus isolation using VeroE6/TMPRSS2 cells. BMJ Open Respir. Res.10.1136/bmjresp-2020-000830 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7907832</ArticleId><ArticleId IdType="pubmed">33627333</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao, H. et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect.11, 277–283. 10.1080/22221751.2021.2023329 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar, P. et al. Identification of potential COVID-19 treatment compounds which inhibit SARS Cov2 prototypic, delta and omicron variant infection. Virology572, 64–71. 10.1016/j.virol.2022.05.004 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9108900</ArticleId><ArticleId IdType="pubmed">35598394</ArticleId></ArticleIdList></Reference><Reference><Citation>Quick, J. nCoV-2019 sequencing protocol v3 (LoCost), on Version created by Josh Quick. https://protocols.io/view/ncov-2019-sequencing-protocol-v3-locost-bh42j8ye (2020).</Citation></Reference><Reference><Citation>Itokawa, K. et al, nCoV-2019 sequencing protocol for illumina. https://www.protocols.io/view/ncov-2019-sequencing-protocol-for-illumina-eq2ly398mgx9/v5 (2021).</Citation></Reference><Reference><Citation>Sasaki, N. Alt_nCov2019_primers ver_N6. https://github.com/nasasaki/Alt_nCov2019_primers (2022).</Citation></Reference><Reference><Citation>Miyamoto, S. et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Medicine3, 249–261. 10.1016/j.medj.2022.02.006 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894731</ArticleId><ArticleId IdType="pubmed">35261995</ArticleId></ArticleIdList></Reference><Reference><Citation>Tani, H. et al. Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein. Virol. J.18, 16. 10.1186/s12985-021-01490-7 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7801864</ArticleId><ArticleId IdType="pubmed">33435994</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato, K., Kawase, M. &amp; Matsuyama, S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J. Virol.87, 12552–12561. 10.1128/JVI.01890-13 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3838146</ArticleId><ArticleId IdType="pubmed">24027332</ArticleId></ArticleIdList></Reference><Reference><Citation>Rucker, G., Qin, H. &amp; Zhang, L. Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor. PLoS ONE18, e0289432. 10.1371/journal.pone.0289432 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10553274</ArticleId><ArticleId IdType="pubmed">37796794</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao, Y. et al. Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75. Cell Host Microbe30, 1527–1539. 10.1016/j.chom.2022.09.018 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9531665</ArticleId><ArticleId IdType="pubmed">36270286</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature603, 706–714. 10.1038/s41586-022-04474-x (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Arons, M. M. et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N. Engl. J. Med.382, 2081–2090. 10.1056/NEJMoa2008457 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200056</ArticleId><ArticleId IdType="pubmed">32329971</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam, A. et al. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro Surveill.10.2807/1560-7917.ES.2020.25.32.2001483 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7427302</ArticleId><ArticleId IdType="pubmed">32794447</ArticleId></ArticleIdList></Reference><Reference><Citation>La Scola, B. et al. Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards. Eur. J. Clin. Microbiol. Infect. Dis.39, 1059–1061. 10.1007/s10096-020-03913-9 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7185831</ArticleId><ArticleId IdType="pubmed">32342252</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama, S. et al. Structural delineation and computational design of SARS-CoV-2-neutralizing antibodies against Omicron subvariants. Nat. Commun.14, 4198. 10.1038/s41467-023-39890-8 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10349087</ArticleId><ArticleId IdType="pubmed">37452031</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. Nature581, 465–469. 10.1038/s41586-020-2196-x (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32235945</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida, I. et al. Investigation of culture cells used for isolation and culture of severe acute respiratory syndrome coronavirus 2, omicron variant, isolated in Tokyo. Ann. Rep. Tokyo Metr. Inst. Public Health74, 43–47 (2023).</Citation></Reference><Reference><Citation>Chen, D. Y. et al. Cell culture systems for isolation of SARS-CoV-2 clinical isolates and generation of recombinant virus. iScience26, 106634. 10.1016/j.isci.2023.106634 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10083141</ArticleId><ArticleId IdType="pubmed">37095858</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfson, K. J. et al. Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol89, 6773–6781. 10.1128/JVI.00649-15 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4468478</ArticleId><ArticleId IdType="pubmed">25903348</ArticleId></ArticleIdList></Reference><Reference><Citation>Alfson, K. J. et al. A single amino acid change in the marburg virus glycoprotein arises during serial cell culture passages and attenuates the virus in a macaque model of disease. mSphere.10.1128/mSphere.00401-17 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5750385</ArticleId><ArticleId IdType="pubmed">29299527</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat, T., Cao, A. &amp; Yin, J. Virus-like Particles: Measures and biological functions. Viruses.10.3390/v14020383 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8877645</ArticleId><ArticleId IdType="pubmed">35215979</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>